Short-Acting Bronchodilators: Examples and Categories
Short-acting bronchodilators include two main classes: short-acting beta-2 agonists (SABAs)—specifically albuterol, levalbuterol, and pirbuterol—and the short-acting anticholinergic ipratropium bromide. 1
Beta-2 Agonists (SABAs)
The primary short-acting beta-2 agonists are:
- Albuterol (most commonly used)
- Levalbuterol
- Pirbuterol
These medications work by relaxing airway smooth muscle and are the treatment of choice for relief of acute asthma symptoms and prevention of exercise-induced bronchospasm 1. They provide rapid symptom relief with effects typically lasting 4-6 hours 2.
Key Clinical Points for SABAs:
- Use as rescue medication only—regularly scheduled daily use is not recommended 1
- If you're using SABAs more than 2 days per week for symptom relief (excluding prevention of exercise-induced bronchospasm), this signals inadequate asthma control and indicates the need to initiate or intensify anti-inflammatory therapy 1
- SABAs have an acceptable safety profile when used appropriately as quick-relief medication 3
Anticholinergics (SAMAs)
Ipratropium bromide is the primary short-acting muscarinic antagonist (SAMA) 1, 4. Another option is oxitropium bromide, though less commonly used 4.
Key Clinical Points for Ipratropium:
- Works by inhibiting muscarinic cholinergic receptors and reducing vagal tone in airways 1
- Provides additive benefit when combined with SABAs in moderate-to-severe exacerbations in the emergency department setting (though not proven beneficial in the hospital inpatient setting) 1
- Can serve as an alternative bronchodilator for patients who cannot tolerate SABAs, though direct comparisons are limited 1
Common Pitfalls to Avoid:
Don't confuse with long-acting bronchodilators: Salmeterol, formoterol, and indacaterol are long-acting agents (LABAs) with duration of at least 12 hours—these are NOT short-acting bronchodilators 1, 2
Monitor SABA overuse: Purchasing or using 3 or more short-acting bronchodilator inhalers per year should trigger reassessment of asthma control 5
Avoid higher-than-necessary doses: Evidence shows increased cardiac adverse events (45% vs 24%) with higher SABA doses without additional clinical benefit 6